PER® Miami Breast Cancer Conference

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses using adjuvant bisphosphonates as a treatment option for patients with breast cancer.

Judy C. Boughey, MD, associate professor of surgery, director, Breast Surgical Oncology Training Program, Mayo Clinic, discusses surgical resection of the primary breast tumor in patients with stage IV breast cancer.

Since its approval in 1998 to treat metastatic breast cancer, the anti-HER2 monoclonal antibody trastuzumab has dramatically expanded life expectancy and improved quality of life for women diagnosed with HER2-positive disease.

Over the past few decades, the optimal margin width for minimizing recurrence after breast-conserving surgery (BCS; lumpectomy) has been a topic of much debate

The large Canadian study that has caused a stir by indicating that mammograms are of no use in women aged 40 to 59 years, and in fact can lead to over-diagnosis of breast cancer, is flawed and misleading

Melvin J. Silverstein, MD, FACS, director, Breast Program Hoag Memorial Hospital, professor of surgery, Keck School of Medicine, University of Southern California, describes oncoplastic surgery.

Hyman B. Muss, MD, discusses optimizing the administration of endocrine therapies with or without mTOR inhibitors for patients with HR-positive metastatic breast cancer

Mark D. Pegram, MD, from the Stanford Cancer Institute, describes research into the antibody-drug conjugate T-DM1, following its FDA approval in February as a treatment for HER2-positive metastatic breast cancer.

This year marks the 30th Annual Miami Breast Cancer Conference, a milestone for Daniel A. Osman, MD, and his wife Lois, who together launched the gathering in 1983 with fewer than 100 attendees and a focus on the then relatively new domain of lumpectomies in breast cancer treatment.

Anees Chagpar, MD, MSc, MA, MPH, Associate Professor of Surgery (Oncology), Director, The Breast Center at Smilow Cancer Hospital at Yale-New Haven, discusses the need for repeat biopsy in patients with breast cancer.

Donna Shalala, PhD, President, University of Miami, discusses the new healthcare reform in the U.S.

Physicians wondering how the Affordable Care Act (ACA) will impact their practices heard a robust defense of the new law from Donna E. Shalala, PhD, on Saturday.

Martine Piccart, MD, PhD, discusses the implications of the HERA trial, which looked at two years compared with one year of trastuzumab after adjuvant chemotherapy in women with HER2-positive breast cancer.

As the genomic era in oncology unfolds, the development of new therapeutics increasingly will involve targeting a range of mutations simultaneously, requiring a "next-generation clinical trials system" to match the advances that technology is delivering.

Two large clinical trials are expected to define the impact that employing genomic tests in treatment decisions has on survival outcomes, according to Martine J. Piccart, MD, PhD.

Oncology leaders are bracing for a host of changes in the healthcare system, not only as a result of the recently upheld insurance reform legislation but also because of continued pressure to control the ever-rising cost of cancer care.

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the field of psycho-oncology.

Burnout is described as a syndrome of "emotional exhaustion, depersonalization, and feelings of low personal accomplishment," and is an increasingly problematic condition among physicians for a multitude of reasons.

Hope S. Rugo, MD, at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the standard for front-line chemotherapy in patients with breast cancer.

An interview with Debu Tripathy, MD, summarizing noteworthy results from the 2012 ASCO Annual Meeting and SABCS, including clinical studies in local, adjuvant, and metastatic breast cancer therapies.

Dr. Debu Tripathy, from the USC Norris Comprehensive Cancer Center, Discusses Breast Cancer Prevention

Recognition of breast cancer subtypes and research into their underlying biologies is driving the development of new therapies.

Dr. Julie Gralow, from the Seattle Cancer Care Alliance, on Adjuvant Bisphosphonates for Breast Cancer

Next-generation immunotherapy in breast cancer treatment is an active field of scientific exploration with the potential to yield a vaccine.

Dr. Daniel Osman, the program chair for the Miami Breast Cancer Conference, Discusses the 29th Annual Meeting

Technological advances in genomics have prompted a "sea change" in breast cancer drug development and treatment.

The choice of breast-conserving surgery over mastectomy is often based on fear of recurrence and death rather than clinical evidence.

Pictures from the Annual Miami Breast Cancer Conference, at the Fontainebleau Miami Beach hotel, in Florida.